252004-38-9

Basic information

• Product Name: Benzenemethanol, 2-fluoro-4-methyl- (9CI)
• Synonyms: Benzenemethanol, 2-fluoro-4-methyl- (9CI);3-Fluoro-4-(hydroxymethyl)toluene, (2-Fluoro-4-methylphenyl)methanol;(2-fluoro-4-methylphenyl)methanol
• CAS NO: 252004-38-9
• Molecular Formula: C₈H₉FO
• Molecular Weight: 140.1548632
• Product Categories: HALIDE
• Mol File: 252004-38-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 218°C at 760 mmHg
• Flash Point: 105.6°C
• Appearance: /
• Density: 1.132g/cm³
• Vapor Pressure: 0.0751mmHg at 25°C
• Refractive Index: 1.518
• CAS DataBase Reference: Benzenemethanol, 2-fluoro-4-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2-fluoro-4-methyl- (9CI)(252004-38-9)
• EPA Substance Registry System: Benzenemethanol, 2-fluoro-4-methyl- (9CI)(252004-38-9)

Safety Data

• Hazardous Substances Data: 252004-38-9(Hazardous Substances Data)

Usage

Chemical compound

Benzenemethanol, 2-fluoro-4-methyl(9CI)

Physical properties

Colorless liquid

Molecular weight

138.16 g/mol

Uses

Intermediate in the synthesis of pharmaceuticals and agrochemicals, insecticidal and larvicidal properties for pest control applications, potential application as a building block in organic synthesis

Hazards

May cause irritation to the skin, eyes, and respiratory system upon exposure

InChI:InChI=1/C8H9FO/c1-6-2-3-7(5-10)8(9)4-6/h2-4,10H,5H2,1H3

Upstream product

• 7697-23-6 2-fluoro-4-methylbenzoic Acid 
• 452-74-4 4-bromo-3-fluorotoluene 

Relevant articles and documents

BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

Isothiazole derivatives useful as anticancer agents

The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2and R3are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.